<p>保诚金融公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Veracyte, Inc.（NASDAQ:VCYT - 免费报告）股票中的持股比例提高了 178.4%。该机构投资者在此期间额外购买了 23,785 股后，持有 37,118 股该生物技术公司的股票。截至其最近的 SEC 文件，保诚金融公司在 Veracyte 的持股价值为 1,003,000 美元。</p>
<p>其他一些对冲基金也调整了对该股票的持仓。Blair William &amp; Co. IL 在第一季度将其在 Veracyte 的持仓提高了 3.5%。Blair William &amp; Co. IL 现在拥有 16,092 股该生物技术公司的股票，价值 477,000 美元，此前在上个季度额外购买了 550 股。先锋集团（Vanguard Group Inc.）在第一季度将其在 Veracyte 的持股比例提高了 0.6%。先锋集团现在拥有 8,263,643 股该生物技术公司的股票，价值 245,017,000 美元，此前在上个季度额外购买了 52,031 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在 Veracyte 的持股比例提高了 2.7%。查尔斯·施瓦布投资管理公司现在拥有 740,631 股该生物技术公司的股票，价值 21,960,000 美元，此前在上个季度额外购买了 19,662 股。Headlands Technologies LLC 在第一季度获得了 Veracyte 的新股份，价值约 48,000 美元。最后，Covestor Ltd 在第一季度将其在 Veracyte 的持股比例提高了 23,936.4%。Covestor Ltd 现在拥有 2,644 股该生物技术公司的股票，价值 78,000 美元，此前在上个季度额外购买了 2,633 股。</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师最近对 VCYT 股票发表了看法。瑞银集团（UBS Group）在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 42.00 美元提高至 48.00 美元，并给予该公司 “买入” 评级。华尔街 Zen 在 11 月 16 日的研究报告中将 Veracyte 的评级从 “买入” 上调至 “强力买入”。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 40.00 美元提高至 43.00 美元，并给予该公司 “持有” 评级。摩根士丹利（Morgan Stanley）在 12 月 1 日的报告中将 Veracyte 的目标价格从 40.00 美元提高至 48.00 美元，并给予该股票 “减持” 评级。最后，古根海姆（Guggenheim）在 11 月 5 日的报告中将 Veracyte 的目标价格从 40.00 美元提高至 45.00 美元，并给予该公司 “买入” 评级。一位投资分析师对该股票给予了 “强力买入” 评级，五位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价格为 45.43 美元。</p>
<p><strong>查看我们最新的 VCYT 股票报告</strong></p>
<h2>Veracyte 股票下跌 5.9%</h2>
<p>NASDAQ:VCYT 周一开盘价为 44.61 美元。该公司的 50 日移动平均线为 39.33 美元，200 日移动平均线为 32.04 美元。Veracyte, Inc.的 12 个月低点为 22.61 美元，12 个月高点为 50.71 美元。该公司的市值为 35.3 亿美元，市盈率为 117.40，贝塔系数为 1.82。</p>
<p>Veracyte（NASDAQ:VCYT - 获取免费报告）在 11 月 4 日发布了其财报。该生物技术公司报告本季度每股收益（EPS）为 0.51 美元，超出分析师共识预期的 0.32 美元，超出幅度为 0.19 美元。该公司本季度的收入为 1.3187 亿美元，而分析师预期为 1.2462 亿美元。Veracyte 的净利润率为 6.12%，股本回报率为 7.23%。与去年同期相比，Veracyte 的收入增长了 13.8%。去年同期，该公司每股收益为 0.33 美元。研究分析师预测，Veracyte, Inc.在当前财政年度将发布 0.68 美元的每股收益。</p>
<h2>Veracyte 内部活动</h2>
<p>在其他新闻中，SVP Annie Mcguire 在 12 月 4 日的交易中出售了 1,422 股 Veracyte 股票。该股票以平均价格 47.30 美元出售，总价值为 67,260.60 美元。交易后，该高级副总裁直接持有该公司 78,499 股股票，价值约 3,713,002.70 美元。此次交易使其持股比例减少了 1.78%。该交易在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Evan/Fa Jones 在 11 月 25 日的交易中出售了 1,106 股该股票。该股票以平均价格 50.25 美元出售，总价值为 55,576.50 美元。出售后，该董事持有该公司 29,362 股股票，价值约 1,475,440.50 美元。此次交易使其持股比例减少了 3.63%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 114,528 股公司股票，价值 4,987,433 美元。1.40% 的股票由公司内部人士持有。</p>
<h2>Veracyte 公司简介</h2>
<p>（免费报告）</p>
<p>Veracyte, Inc.从事诊断产品的研究、开发和商业化。该公司的产品组合包括 Afirma、Percepta 和 Envisia。其旨在治疗甲状腺癌、改善肺癌筛查以及澄清特发性肺纤维化的诊断。该公司由 Bonnie H.创立。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Veracyte 更好</li>
<li>恒生指数是什么？</li>
<li>Rubrik 的巨大反弹：为什么下一轮上涨可能会很快</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>Five Below 和 Dollar Tree 的收益信号显示购物者的转变</li>
<li>支撑位是什么？</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 VCYT 股票吗？</strong> 请访问 HoldingsChannel.com，获取 Veracyte, Inc.（NASDAQ:VCYT - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNZVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNZVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Veracyte 吗？</h2>
<p>在考虑 Veracyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Veracyte 并不在名单上。</p>
<p>虽然 Veracyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VCYT

<p>保诚金融公司在第二季度将其在 Veracyte, Inc.的股份增加了 178.4%，目前持有 37,118 股，价值 100 万美元。分析师已调整了对 Veracyte 的评级和目标价格，普遍评级为 “适度买入”，目标价格为 45.43 美元。Veracyte 的股票开盘价为 44.61 美元，市值为 35.3 亿美元</p>

<p>Prudential Financial Inc. grew its stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 178.4% during the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 37,118 shares of the biotechnology company's stock after acquiring an additional 23,785 shares during the period. Prudential Financial Inc.'s holdings in Veracyte were worth $1,003,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>保诚金融公司在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Veracyte, Inc.（NASDAQ:VCYT - 免费报告）股票中的持股比例提高了 178.4%。该机构投资者在此期间额外购买了 23,785 股后，持有 37,118 股该生物技术公司的股票。截至其最近的 SEC 文件，保诚金融公司在 Veracyte 的持股价值为 1,003,000 美元。</p>
</div><p>A number of other hedge funds have also modified their holdings of the stock. Blair William &amp; Co. IL boosted its position in Veracyte by 3.5% during the first quarter. Blair William &amp; Co. IL now owns 16,092 shares of the biotechnology company's stock valued at $477,000 after purchasing an additional 550 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Veracyte by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 8,263,643 shares of the biotechnology company's stock worth $245,017,000 after purchasing an additional 52,031 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Veracyte by 2.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 740,631 shares of the biotechnology company's stock worth $21,960,000 after purchasing an additional 19,662 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Veracyte during the 1st quarter valued at about $48,000. Finally, Covestor Ltd grew its stake in shares of Veracyte by 23,936.4% in the 1st quarter. Covestor Ltd now owns 2,644 shares of the biotechnology company's stock valued at $78,000 after buying an additional 2,633 shares in the last quarter.</p>
<div class="lb-trans"><p>其他一些对冲基金也调整了对该股票的持仓。Blair William &amp; Co. IL 在第一季度将其在 Veracyte 的持仓提高了 3.5%。Blair William &amp; Co. IL 现在拥有 16,092 股该生物技术公司的股票，价值 477,000 美元，此前在上个季度额外购买了 550 股。先锋集团（Vanguard Group Inc.）在第一季度将其在 Veracyte 的持股比例提高了 0.6%。先锋集团现在拥有 8,263,643 股该生物技术公司的股票，价值 245,017,000 美元，此前在上个季度额外购买了 52,031 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在 Veracyte 的持股比例提高了 2.7%。查尔斯·施瓦布投资管理公司现在拥有 740,631 股该生物技术公司的股票，价值 21,960,000 美元，此前在上个季度额外购买了 19,662 股。Headlands Technologies LLC 在第一季度获得了 Veracyte 的新股份，价值约 48,000 美元。最后，Covestor Ltd 在第一季度将其在 Veracyte 的持股比例提高了 23,936.4%。Covestor Ltd 现在拥有 2,644 股该生物技术公司的股票，价值 78,000 美元，此前在上个季度额外购买了 2,633 股。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts recently weighed in on VCYT shares. UBS Group raised their price objective on shares of Veracyte from $42.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Veracyte from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Sunday, November 16th. Canaccord Genuity Group lifted their price objective on shares of Veracyte from $40.00 to $43.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, November 5th. Morgan Stanley upped their price objective on shares of Veracyte from $40.00 to $48.00 and gave the stock an &#34;underweight&#34; rating in a report on Monday, December 1st. Finally, Guggenheim raised their target price on Veracyte from $40.00 to $45.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.43.</p>
<div class="lb-trans"><p>几位股票分析师最近对 VCYT 股票发表了看法。瑞银集团（UBS Group）在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 42.00 美元提高至 48.00 美元，并给予该公司 “买入” 评级。华尔街 Zen 在 11 月 16 日的研究报告中将 Veracyte 的评级从 “买入” 上调至 “强力买入”。Canaccord Genuity Group 在 11 月 5 日的研究报告中将 Veracyte 的目标价格从 40.00 美元提高至 43.00 美元，并给予该公司 “持有” 评级。摩根士丹利（Morgan Stanley）在 12 月 1 日的报告中将 Veracyte 的目标价格从 40.00 美元提高至 48.00 美元，并给予该股票 “减持” 评级。最后，古根海姆（Guggenheim）在 11 月 5 日的报告中将 Veracyte 的目标价格从 40.00 美元提高至 45.00 美元，并给予该公司 “买入” 评级。一位投资分析师对该股票给予了 “强力买入” 评级，五位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价格为 45.43 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on VCYT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VCYT 股票报告</strong></p>
</div><h2>Veracyte Stock Down 5.9%</h2>
<div class="lb-trans"><h2>Veracyte 股票下跌 5.9%</h2>
</div><p>NASDAQ:VCYT opened at $44.61 on Monday. The company's 50 day moving average is $39.33 and its 200-day moving average is $32.04. Veracyte, Inc. has a 12 month low of $22.61 and a 12 month high of $50.71. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of 117.40 and a beta of 1.82.</p>
<div class="lb-trans"><p>NASDAQ:VCYT 周一开盘价为 44.61 美元。该公司的 50 日移动平均线为 39.33 美元，200 日移动平均线为 32.04 美元。Veracyte, Inc.的 12 个月低点为 22.61 美元，12 个月高点为 50.71 美元。该公司的市值为 35.3 亿美元，市盈率为 117.40，贝塔系数为 1.82。</p>
</div><p>Veracyte (NASDAQ:VCYT - Get Free Report) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.32 by $0.19. The business had revenue of $131.87 million for the quarter, compared to analyst estimates of $124.62 million. Veracyte had a net margin of 6.12% and a return on equity of 7.23%. Veracyte's revenue was up 13.8% compared to the same quarter last year. During the same period last year, the business posted $0.33 EPS. Research analysts predict that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Veracyte（NASDAQ:VCYT - 获取免费报告）在 11 月 4 日发布了其财报。该生物技术公司报告本季度每股收益（EPS）为 0.51 美元，超出分析师共识预期的 0.32 美元，超出幅度为 0.19 美元。该公司本季度的收入为 1.3187 亿美元，而分析师预期为 1.2462 亿美元。Veracyte 的净利润率为 6.12%，股本回报率为 7.23%。与去年同期相比，Veracyte 的收入增长了 13.8%。去年同期，该公司每股收益为 0.33 美元。研究分析师预测，Veracyte, Inc.在当前财政年度将发布 0.68 美元的每股收益。</p>
</div><h2>Insider Activity at Veracyte</h2>
<div class="lb-trans"><h2>Veracyte 内部活动</h2>
</div><p>In other news, SVP Annie Mcguire sold 1,422 shares of Veracyte stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $47.30, for a total value of $67,260.60. Following the transaction, the senior vice president directly owned 78,499 shares in the company, valued at approximately $3,713,002.70. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Evan/ Fa Jones sold 1,106 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $50.25, for a total value of $55,576.50. Following the sale, the director owned 29,362 shares of the company's stock, valued at approximately $1,475,440.50. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 114,528 shares of company stock valued at $4,987,433. 1.40% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，SVP Annie Mcguire 在 12 月 4 日的交易中出售了 1,422 股 Veracyte 股票。该股票以平均价格 47.30 美元出售，总价值为 67,260.60 美元。交易后，该高级副总裁直接持有该公司 78,499 股股票，价值约 3,713,002.70 美元。此次交易使其持股比例减少了 1.78%。该交易在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Evan/Fa Jones 在 11 月 25 日的交易中出售了 1,106 股该股票。该股票以平均价格 50.25 美元出售，总价值为 55,576.50 美元。出售后，该董事持有该公司 29,362 股股票，价值约 1,475,440.50 美元。此次交易使其持股比例减少了 3.63%。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 114,528 股公司股票，价值 4,987,433 美元。1.40% 的股票由公司内部人士持有。</p>
</div><h2>Veracyte Company Profile</h2>
<div class="lb-trans"><h2>Veracyte 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.</p>
<div class="lb-trans"><p>Veracyte, Inc.从事诊断产品的研究、开发和商业化。该公司的产品组合包括 Afirma、Percepta 和 Envisia。其旨在治疗甲状腺癌、改善肺癌筛查以及澄清特发性肺纤维化的诊断。该公司由 Bonnie H.创立。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Veracyte</li>
<li>What is the Hang Seng index?</li>
<li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li>
<li>What is a support level?</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Veracyte 更好</li>
<li>恒生指数是什么？</li>
<li>Rubrik 的巨大反弹：为什么下一轮上涨可能会很快</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>Five Below 和 Dollar Tree 的收益信号显示购物者的转变</li>
<li>支撑位是什么？</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VCYT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 VCYT 股票吗？</strong> 请访问 HoldingsChannel.com，获取 Veracyte, Inc.（NASDAQ:VCYT - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkNZVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VCYT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Veracyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Veracyte 吗？</h2>
</div><p>Before you consider Veracyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Veracyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veracyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Veracyte 并不在名单上。</p>
</div><p>While Veracyte currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Veracyte 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

保德信金融公司在 Veracyte, Inc. $VCYT 中持有价值 100 万美元的头寸